BioCentury | Mar 6, 2021
Emerging Company Profile

Araris: universal linkers for antibody-drug conjugates

Araris is developing antibody-drug conjugate linker technology that could widen the therapeutic window for ADCs by improving their stability and solubility. In addition, the Swiss biotech’s peptide linkers...
BioCentury | Feb 9, 2021
Product Development

Feb. 8 Quick Takes: FDA approves TG’s lymphoma therapy; plus uniQure, Astellas, BMS, Viiv, Avrobio and Veru

FDA approved Ukoniq umbralisib from TG Therapeutics Inc. (NASDAQ:TGTX) to treat relapsed or refractory marginal zone lymphoma following anti-CD20 treatment, or relapsed or refractory follicular lymphoma in a fourth-line setting. TG believes the once-daily oral...
BioCentury | Dec 31, 2020
Distillery Therapeutics

BRD4 as a DMD target

DISEASE CATEGORY: Musculoskeletal INDICATION: Muscular dystrophy Inhibiting BRD4 and other BET proteins could treat Duchenne muscular dystrophy (DMD). Levels of BRD4 protein in paravertebral muscles were higher in four DMD patients than in two healthy volunteers....
BioCentury | Dec 12, 2020
Product Development

Dec. 11 Quick Takes: AZ to run combo trial with Sputnik; plus Phase III hits for Lilly, AbbVie and TG, data from Immutep, NVS, Mycovia, Sarepta and Greenwich

Russian and AZ COVID vaccines in combo trialAstraZeneca plc (LSE:AZN; NASDAQ:AZN) will begin by year-end a clinical trial of its AZD1222, developed with the University of Oxford, in combination with the adenovirus serotype 26 (Ad26)...
BioCentury | Dec 12, 2020

CHMP’s December opinions include restrictions for Veklury in COVID, support for Daiichi, Seagen breast cancer drugs

In its December opinions, EMA’s CHMP recommended a restriction for Gilead’s Veklury, specifying that COVID-19 patients should be on low- or high-flow oxygen or other non-invasive ventilation at the start of treatment.  The committee also...
BioCentury | Aug 15, 2020
Product Development

Aug. 14 Quick Takes: Challenge data for CanSino COVID-19 vaccine; plus Warp Speed-McKesson, BioMarin, TG, Solasia-Isofol

CanSino vaccine stops COVID-19 in mice, ferretsMice given a single intranasal immunization with Ad5-nCoV from CanSino Biologics Inc. (HKEX:6185; Shanghai:688185) and then challenged with mouse-adapted SARS-CoV-2 had no detectable virus in the lungs and nose...
BioCentury | May 15, 2020

As biotech IPO pace quickens, ADC Therapeutics garners largest postmoney valuation of the year

Adding to a steady drip of biotechs testing U.S. public markets, ADC Therapeutics became the latest to climb on its trading debut after pricing an upsized IPO. ADC Therapeutics S.A. (NYSE:ADCT) rose $10.65 (56%) to...
BioCentury | May 9, 2020
Management Tracks

O’Connor joins TG Therapeutics as CSO; plus changes at FogPharma, Gemini, Dicerna, Akcea and more

Cancer and autoimmune company TG Therapeutics Inc. (NASDAQ:TGTX) hired Owen O’Connor as CSO. He was director of the Center for Lymphoid Malignancies at Columbia University Medical Center. RNAi company Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) said retiring...
BioCentury | May 7, 2020

May 6 Quick Takes: Grail raises year’s largest venture round; plus fresh funds for Insmed, Kura, TG, BerGenBio, Limbix and Kineta

New round pushes Grail’s venture tally over $1.9B Grail Inc. raised $390 million in a series D round, marking the year's largest venture round to date. New backers, including Public Sector Pension Investment Board and...
BioCentury | May 6, 2020
Product Development

May 5 Quick Takes: Data propel Adverum, TG, Akebia stocks; plus Tolmar, SRI-Exscientia, Sino-GeoVax

TG’s combo meets Phase III leukemia endpoint TG Therapeutics Inc. (NASDAQ:TGTX) climbed $4.23 (34%) to $16.69 on Tuesday after CD20 inhibitor ublituximab plus PI3Kδ inhibitor umbralisib met the primary endpoint of progression-free survival (PFS) in...
Items per page:
1 - 10 of 445